Is ARDS or CLVR more profitable?

Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Clever Leaves N/A N/A N/A

Is ARDS or TRVN more profitable?

Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Trevena N/A N/A -119.55%

Which has stronger earnings and valuation, BPTH or ARDS?

Aridis Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Path N/A N/A -$16.08M -$1.09 N/A Aridis Pharmaceuticals N/A N/A -$30.37M -$0.02 N/A

Is BPTH or ARDS more profitable?

Aridis Pharmaceuticals' return on equity of 0.00% beat Bio-Path's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Path N/A -2,842.40% -337.48% Aridis Pharmaceuticals N/A N/A N/A

Is ARDS or SYRS more profitable?

Aridis Pharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Aridis Pharmaceuticals N/A N/A N/A Syros Pharmaceuticals N/A -3,369.56% -97.04%

Is NAVB or ARDS more profitable?

Company Net Margins Return on Equity Return on Assets Navidea Biopharmaceuticals N/A N/A N/A Aridis Pharmaceuticals N/A N/A N/A

Aridis Pharmaceuticals (ARDS) Competitors

$0.0001 0.00 (0.00%)

As of 02:37 PM Eastern

Compare

ARDS vs. CLVR, TRVN, BPTH, SYRS, and NAVB

Should you buy Aridis Pharmaceuticals stock or one of its competitors? Aridis Pharmaceuticals's main competitors and comparable companies include Clever Leaves (CLVR), Trevena (TRVN), Bio-Path (BPTH), Syros Pharmaceuticals (SYRS), and Navidea Biopharmaceuticals (NAVB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aridis Pharmaceuticals compare to Clever Leaves?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Clever Leaves (NASDAQ:CLVR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Clever Leaves	N/A	N/A	N/A

Clever Leaves has higher revenue and earnings than Aridis Pharmaceuticals. Aridis Pharmaceuticals is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	-$0.02	N/A
Clever Leaves	$17.42M	0.00	-$17.90M	-$7.56	N/A

Aridis Pharmaceuticals has a beta of 47.61, indicating that its share price is 4,661% more volatile than the broader market. Comparatively, Clever Leaves has a beta of 3892.08, indicating that its share price is 389,108% more volatile than the broader market.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Clever Leaves	Neutral

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 6.9% of Clever Leaves shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 8.2% of Clever Leaves shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Clever Leaves beats Aridis Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Trevena?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Trevena (NASDAQ:TRVN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Aridis Pharmaceuticals has a beta of 47.61, meaning that its stock price is 4,661% more volatile than the broader market. Comparatively, Trevena has a beta of -1.99, meaning that its stock price is 299% less volatile than the broader market.

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Comparatively, 2.7% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aridis Pharmaceuticals has higher earnings, but lower revenue than Trevena. Aridis Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	-$0.02	N/A
Trevena	$443K	0.14	-$40.29M	-$47.04	N/A

In the previous week, Trevena's average media sentiment score of 0.48 beat Aridis Pharmaceuticals' score of 0.00 indicating that Trevena is being referred to more favorably in the news media.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Trevena	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Trevena	N/A	N/A	-119.55%

Summary

Aridis Pharmaceuticals beats Trevena on 5 of the 9 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Bio-Path?

Bio-Path (NASDAQ:BPTH) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

5.7% of Bio-Path shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 0.7% of Bio-Path shares are held by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Bio-Path has a beta of -0.44, suggesting that its share price is 144% less volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 47.61, suggesting that its share price is 4,661% more volatile than the broader market.

In the previous week, Bio-Path's average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Bio-Path	Neutral
Aridis Pharmaceuticals	Neutral

Aridis Pharmaceuticals is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Path	N/A	N/A	-$16.08M	-$1.09	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	-$0.02	N/A

Aridis Pharmaceuticals' return on equity of 0.00% beat Bio-Path's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Path	N/A	-2,842.40%	-337.48%
Aridis Pharmaceuticals	N/A	N/A	N/A

Summary

Aridis Pharmaceuticals beats Bio-Path on 6 of the 8 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Syros Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Aridis Pharmaceuticals has higher earnings, but lower revenue than Syros Pharmaceuticals. Aridis Pharmaceuticals is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	-$0.02	N/A
Syros Pharmaceuticals	$386K	0.03	-$164.57M	-$3.03	N/A

Aridis Pharmaceuticals' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aridis Pharmaceuticals	N/A	N/A	N/A
Syros Pharmaceuticals	N/A	-3,369.56%	-97.04%

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aridis Pharmaceuticals has a beta of 47.61, suggesting that its stock price is 4,661% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.80 beat Aridis Pharmaceuticals' score of 0.00 indicating that Syros Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aridis Pharmaceuticals	Neutral
Syros Pharmaceuticals	Positive

Summary

Aridis Pharmaceuticals and Syros Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does Aridis Pharmaceuticals compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

Company	Net Margins	Return on Equity	Return on Assets
Navidea Biopharmaceuticals	N/A	N/A	N/A
Aridis Pharmaceuticals	N/A	N/A	N/A

Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 47.61, meaning that its stock price is 4,661% more volatile than the broader market.

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Navidea Biopharmaceuticals has higher revenue and earnings than Aridis Pharmaceuticals. Aridis Pharmaceuticals is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Navidea Biopharmaceuticals	$8.13K	0.00	-$15.18M	-$0.21	N/A
Aridis Pharmaceuticals	N/A	N/A	-$30.37M	-$0.02	N/A

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Navidea Biopharmaceuticals	Neutral
Aridis Pharmaceuticals	Neutral

Summary

Navidea Biopharmaceuticals beats Aridis Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Get Aridis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARDS vs. The Competition

Export

Metric	Aridis Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5K	$12.13B	$7.18B	$13.18B
Dividend Yield	N/A	2.63%	2.52%	19.60%
P/E Ratio	-0.01	626.67	195.97	18.94
Price / Sales	N/A	746.64	564.50	78.56
Price / Cash	N/A	84.08	76.68	52.75
Price / Book	N/A	9.15	10.51	5.92
Net Income	-$30.37M	$2.82B	$3.50B	$380.90M
7 Day Performance	N/A	-4.55%	-4.32%	-4.38%
1 Month Performance	N/A	-8.50%	-8.64%	-7.25%
1 Year Performance	N/A	-6.15%	2.05%	-4.95%

Aridis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARDS Aridis Pharmaceuticals	N/A	$0.00 flat	N/A	-50.0%	$5K	N/A	N/A	37
CLVR Clever Leaves	N/A	$0.01 +9,900.0%	N/A	N/A	$18K	$17.42M	N/A	560
TRVN Trevena	N/A	$0.01 flat	N/A	+450.0%	$12K	$443K	N/A	23
BPTH Bio-Path	N/A	$0.00 flat	N/A	-99.6%	$11K	N/A	N/A	10	Gap Down
SYRS Syros Pharmaceuticals	N/A	$0.00 flat	N/A	-92.0%	$11K	$386K	N/A	68	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARDS) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aridis Pharmaceuticals (ARDS) Competitors

ARDS vs. CLVR, TRVN, BPTH, SYRS, and NAVB

How does Aridis Pharmaceuticals compare to Clever Leaves?

Summary

How does Aridis Pharmaceuticals compare to Trevena?

Summary

How does Aridis Pharmaceuticals compare to Bio-Path?

Summary

How does Aridis Pharmaceuticals compare to Syros Pharmaceuticals?

Summary

How does Aridis Pharmaceuticals compare to Navidea Biopharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDS vs. The Competition

Aridis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aridis Pharmaceuticals (ARDS) Competitors

ARDS vs. CLVR, TRVN, BPTH, SYRS, and NAVB

How does Aridis Pharmaceuticals compare to Clever Leaves?

Is ARDS or CLVR more profitable?

Which has preferable earnings and valuation, ARDS or CLVR?

Which has more risk & volatility, ARDS or CLVR?

Does the media prefer ARDS or CLVR?

Do insiders & institutionals believe in ARDS or CLVR?

Summary

How does Aridis Pharmaceuticals compare to Trevena?

Which has more volatility and risk, ARDS or TRVN?

Do institutionals & insiders hold more shares of ARDS or TRVN?

Which has higher earnings and valuation, ARDS or TRVN?

Does the media refer more to ARDS or TRVN?

Is ARDS or TRVN more profitable?

Summary

How does Aridis Pharmaceuticals compare to Bio-Path?

Do insiders and institutionals believe in BPTH or ARDS?

Which has more risk and volatility, BPTH or ARDS?

Does the media prefer BPTH or ARDS?

Which has stronger earnings and valuation, BPTH or ARDS?

Is BPTH or ARDS more profitable?

Summary

How does Aridis Pharmaceuticals compare to Syros Pharmaceuticals?

Which has preferable earnings and valuation, ARDS or SYRS?

Is ARDS or SYRS more profitable?

Do institutionals and insiders believe in ARDS or SYRS?

Which has more risk and volatility, ARDS or SYRS?

Does the media favor ARDS or SYRS?

Summary

How does Aridis Pharmaceuticals compare to Navidea Biopharmaceuticals?

Is NAVB or ARDS more profitable?

Which has more volatility and risk, NAVB or ARDS?

Do institutionals & insiders believe in NAVB or ARDS?

Which has preferable valuation and earnings, NAVB or ARDS?

Does the media favor NAVB or ARDS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARDS vs. The Competition

Aridis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools